Xenon Pharmaceuticals (XENE) Competitors $31.49 -0.10 (-0.32%) Closing price 04:00 PM EasternExtended Trading$31.49 0.00 (0.00%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XENE vs. BBIO, VRNA, BPMC, ROIV, ELAN, RGC, LEGN, RVMD, GRFS, and TGTXShould you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Legend Biotech (LEGN), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Xenon Pharmaceuticals vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Elanco Animal Health Regencell Bioscience Legend Biotech Revolution Medicines Grifols TG Therapeutics Xenon Pharmaceuticals (NASDAQ:XENE) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations. Do insiders & institutionals believe in XENE or BBIO? 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 5.5% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate XENE or BBIO? Xenon Pharmaceuticals presently has a consensus price target of $54.82, indicating a potential upside of 74.08%. BridgeBio Pharma has a consensus price target of $61.50, indicating a potential upside of 33.99%. Given Xenon Pharmaceuticals' higher possible upside, research analysts plainly believe Xenon Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer XENE or BBIO? In the previous week, BridgeBio Pharma had 20 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 23 mentions for BridgeBio Pharma and 3 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.59 beat BridgeBio Pharma's score of 0.28 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BridgeBio Pharma 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, XENE or BBIO? Xenon Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Which has higher valuation and earnings, XENE or BBIO? Xenon Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M256.23-$234.33M-$3.23-9.75BridgeBio Pharma$221.90M39.28-$535.76M-$3.53-13.00 Is XENE or BBIO more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -32.44% -30.84% BridgeBio Pharma -524.25%N/A -94.43% SummaryXenon Pharmaceuticals beats BridgeBio Pharma on 8 of the 15 factors compared between the two stocks. Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XENE vs. The Competition Export to ExcelMetricXenon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.42B$2.93B$5.52B$9.41BDividend YieldN/A2.48%4.00%4.05%P/E Ratio-9.7517.3226.9619.00Price / Sales256.23306.01446.2499.61Price / CashN/A40.8024.9928.17Price / Book3.187.648.145.70Net Income-$234.33M-$55.16M$3.24B$257.84M7 Day Performance-3.40%1.84%1.12%1.87%1 Month Performance-1.75%13.83%8.39%13.28%1 Year Performance-26.30%4.18%34.01%19.15% Xenon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals3.6588 of 5 stars$31.49-0.3%$54.82+74.1%-26.1%$2.42B$9.43M-9.75210Positive NewsBBIOBridgeBio Pharma4.5942 of 5 stars$47.69+2.6%$61.20+28.3%+77.6%$9.06B$221.90M-13.51400Analyst ForecastVRNAVerona Pharma PLC American Depositary Share2.6531 of 5 stars$104.67-0.2%$109.00+4.1%+357.1%$8.91B$42.28M-52.3430High Trading VolumeBPMCBlueprint Medicines0.98 of 5 stars$129.36+0.0%$128.25-0.9%N/A$8.35B$508.82M-52.37640Analyst UpgradeHigh Trading VolumeROIVRoivant Sciences2.8084 of 5 stars$11.63+2.4%$16.50+41.9%+4.0%$7.91B$29.05M-46.52860Positive NewsELANElanco Animal Health2.0428 of 5 stars$14.88-0.2%$15.33+3.1%+16.2%$7.39B$4.44B20.109,000Analyst RevisionRGCRegencell Bioscience0.2457 of 5 stars$14.68-0.5%N/AN/A$7.29BN/A0.0010Gap DownLEGNLegend Biotech3.6919 of 5 stars$39.44+1.2%$72.70+84.3%-29.2%$7.25B$627.24M-66.852,609Positive NewsAnalyst RevisionRVMDRevolution Medicines4.5544 of 5 stars$38.37+0.9%$68.00+77.2%-17.0%$7.15B$11.58M-9.59250GRFSGrifols3.5253 of 5 stars$9.72-0.2%$10.30+6.0%+23.1%$6.68B$7.81B8.3123,822TGTXTG Therapeutics3.6759 of 5 stars$38.92+5.0%$43.80+12.5%+80.5%$6.18B$329M162.17290Positive News Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Elanco Animal Health Alternatives Regencell Bioscience Alternatives Legend Biotech Alternatives Revolution Medicines Alternatives Grifols Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XENE) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XENE Stock Alerts